Skip to main content
. 2020 Aug 17;5(4):e000774. doi: 10.1136/esmoopen-2020-000774

Figure 1.

Figure 1

(A) Proportion of patients who received treatment with CDKi according to the line of therapy and year of treatment initiation. (B) Dose modification and treatment discontinuation rates in patients who received CDKi. CDKi, cyclin-dependent kinase inhibitor.